Clinical Trial

The PEBBLES Study - Testing a Strategy for Preventing Eczema and Food Allergy in High Risk Infants

Study acronym: PEBBLES
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a phase III, single blind (outcome assessor is blinded), randomised controlled multicentre trial of the effect of EpiCeram emollient for improving and maintaining skin barrier function and reducing incidence of eczema and food allergy in high risk infants. A total of 760 participants with a first degree family history of allergic disease (asthma, eczema, allergic rhinitis or food allergy) will be recruited (380 each group) from maternity wards of three hospitals.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2018-09-09; most recent amendment 2023-05-09.
Status change: Recruiting → Active, Not Recruiting 2021-04-27
Trial Details
NCT Number NCT03667651
Lead Sponsor University of Melbourne
Conditions Eczema, Asthma, Allergy;Food
Enrollment 760 participants
Start Date 2018-03-06
Primary Completion 2027-05-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2023-05-10